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Summary 
The CD58 binding site on human CD2 was recently shown by nuclear magnetic resonance  structural 
data in conjunction with site-directed mutagenesis to be a highly charged surface area covering 
"~770A  2 on the major AGFCC'C" face  of the CD2 immunoglobulin-like (Ig-like) NH2-terminal 
domain. Here we have identified the other binding surface of the CD2-CD58 adhesion pair by 
mutating charged residues shared among CD2 ligands (human CD58, sheep CD58, and human 
CD48) that are predicted to be solvent exposed on a molecular model of the Ig-like adhesion 
domain of human CD58. This site includes B strand residues along the C  strand (E25, K29, 
and K30), in the middle of the C' strand (E37) and in the G strand (K87). In addition,  several 
residues on the CC' loop (K32, D33, and K34) form this site. Thus, the interaction  between 
CD2 and CD58 involves the major B sheet surface of each adhesion domain. Possible docking 
orientations for the CD2-CD58 molecular complex are offered. Strict conservation of human 
and sheep CD58 residues within the involved C  and C'  strands and CC' loop  suggests that 
this region is particularly important for stable formation of the CD2-CD58 complex. The analysis 
of this complex offers molecular insight into the nature of a receptor-ligand pair involving two 
Ig family members. 
T 
he interaction of human CD2 on T lymphocytes with 
CD58 on the surface of antigen-presenting,  epithelial, 
endothelial,  and target cells of various types is critical for 
T lymphocytes to mediate their regulatory and effector func- 
tions (1-3). The adhesion domains of CD2 and CD58 facili- 
tate the antigen recognition process by stabilizing cell-cell 
contact (4, 5). In addition, ligation of CD2 by CD58 or anti- 
CD2 mAbs provides signals via the CD2 cytoplasmic tail, 
thereby lowering the activation threshold for TCR triggering 
(6-11).  CD2 also facilitates cytotoxic function of NK cells 
through similar mechanisms  (12-14). 
The membrane distal NH2-terminal domains  of human 
CD2  and  human  CD58  bind  to  one  another  with  a 
micromolar affinity (15-17). This modest, monomeric binding 
activity is amplified by multimeric interaction at the cell-cell 
interface resulting from rapid redistribution of CD2 to the 
intercellular junction (5, 18). Human CD2 also interacts with 
sheep CD58, providing the molecular basis for the fortuitous 
observation that human T cells and sheep erythrocytes form 
aggregates,  or "rosettes" in vitro  (19-23).  This rosetting 
phenomenon was used to enumerate T lymphocytes in humans 
long before the discovery of CD2 (20-23).  Human CD2 in- 
teracts with a second structurally related human ligand, CD48 
(24). However,  the affinity of the CD2-CD48 interaction 
is 2 orders of magnitude weaker (10 -4 M) than that of the 
CD2-CD58 interaction and hence, is unable to support cell 
adhesion in an in vitro assay (24). In the murine system, in 
contrast, CD48 is the only known ligand for CD2 (25). Thus, 
it appears that the ligands of CD2 have diverged during the 
evolution  of humans and rodents (24). 
Molecular  cloning of human CD2 and CD58 indicated 
that their gene products are r  homologous at the amino 
acid level and suggested their structure to be Ig-like (26-30). 
Nuclear magnetic resonance (NMR) 1 spectroscopy and x-ray 
crystallographic studies confirm that both rat and human CD2 
adhesion domains adopt the predicted Ig fold (31-34). Human 
1 Abbreviations used in this paper: aa, amino  acid; NMR, nuclear  magnetic 
resonance. 
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human CD2 and CD58, implying that human CD58 may 
have evolved from CD48 (24, 35, 36). The human CD2 and 
CD58 genes are located on chromosome lp and the CD48 
gene is on lq (36, 37). These genes are tightly linked with 
the ATP1A genes on chromosome 1 which have evolved by 
gene duplication (36-38). By inference, it is likely that dupli- 
cation of a primordial gene also gave rise to the structurally 
related CD2,  CD58,  and CD48 genes (36, 38).  In this re- 
gard, the human genomic organization of CD2 and CD58 
is similar except for an additional exon in human CD58 which 
contains the alternative splice sites for the phosphatidyl-inositol 
(PI), linked and transmembrane forms of CD58 (39, and Wal- 
lich, R., personal communication). However, the tissue dis- 
tributions of CD58, CD48, and CD2 markedly differ from 
one another. CD58 is ubiquitously expressed in many diverse 
cell types, whereas CD48 expression is restricted to leuko- 
cytes and human CD2 is limited to T and NK cells (40-42). 
Site-directed mutagenesis studies based on the NMR struc- 
ture of the adhesion domain of human CD2 defines the CD58 
binding surface as a highly charged surface area restricted to 
the AGFCC'C" face of its Ig-like domain (43). An indepen- 
dent mutagenesis study predicated on a homology model of 
the human CD2 adhesion domain yields similar conclusions 
(44). Given these findings, it seems likely that a charged sur- 
face on the NH2-terminal domain of human CD58 might 
bind to CD2. Based on this speculation and the known se- 
quences of human CD2 ligands (human CD58, human CD48, 
and sheep CD58), we selected charged residues on human 
CD58 that are conserved among the CD2 ligands for site- 
directed mutagenesis. The ability of mutant CD58 molecules 
to bind CD2 was then analyzed and the binding site for human 
CD2 on CD58 was mapped. In addition, the predicted struc- 
tural features shared in common by the other CD2 ligands 
permits us to infer how they might bind to CD2 as well. 
Materials  and Methods 
Antibodies.  TS2/9 mAb was provided  by Dr. T. Springer (Center 
for Blood Research, Boston, MA). All other anti-CD58 mAbs used 
in this study were generously  provided  by Dr. Stefan  Meuer (German 
Cancer Research Center, Heidelberg, Germany) (45). The CD58 
heteroantisera, Rb202, was provided by Dr. Laurlee Osborn (Bio- 
gen Inc.,  Cambridge,  MA)  (17). 
Site-directed  Mutagenesis.  A 0.8-kb CD58 cDNA fragment was 
excised from CDM8 (28) with XbaI and subcloned into the XbaI 
site of M13mp18 in order to generate site-directed mutants. Muta- 
genesis and subcloning of mutant CD58 cDNA molecules into 
the CDM8 expression vector was conducted as previously described 
(43). The entire adhesion domain of each variant was sequenced 
to exclude second-site mutations. 
Transfection, Binding Analysis, and Immunofluorescence Assays. 
CHO cells were cultured and transfected with CD58 cDNAs as 
previously described (24). Stable CHO cell lines expressing mu- 
tant CD58 at copy numbers comparable or higher than wtCD58- 
transfected CHO cells were derived by fluorescence-activated  cell 
sorting of the parental transfectants. For this purpose, we used a 
rabbit heteroantisera specific  for the extracellular segment of CD58, 
termed RB202 (1:100 dilution)  followed by staining with FITC- 
conjugated goat anti-rabbit Ig (Tago, Inc., Burlingame, CA). For 
binding studies, CHO cells expressing mutant or wtCD58 mole- 
cules were plated in triplicates at 5  ￿  104 cells/well in 24-well 
plates and analyzed for CD2 binding  using  SlCr-labeled Jurkat 
cells as previously described (24). For experiments aimed at iden- 
tifying anti-CD58 mAb binding residues on human CD58, non- 
saturating concentrations of mAbs (yielding between 50 and 90% 
of  maximum fluorescence)  on wtCD58-transfected CHO cells  when 
developed  using a goat anti-mouse Ig labeled  with FITC (BioWhit- 
taker, Inc., Walkersville, MD) were used to optimize sensitivity. 
Cell-bound immunofluorescence  was determined using a FACScan  | 
(Becton Dickinson & Co., Mountain View, CA) as described (see 
legend to Table 1). 
Molecular Modeling of the Human CD58 Adhesion Domain.  Two 
three-dimensional molecular models of the adhesion domain of 
human CD58 were developed independently, based on homology 
with the known three-dimensional NMR structure of the human 
CD2 adhesion domain (32, 33). 
The first model was based on a structural alignment of human 
CD2, rat CD2, human CD4, human CD8, and REI Ig molecules 
(31-33, 46-48). This produced a sequence alignment to which the 
CD58  sequence was aligned. The coordinates of the main chain 
secondary structure regions were taken from human CD2 (average 
of 18 newly refined NMR structures, energy minimized). The con- 
formations of the loops were modeled on the structure whose se- 
quence in the loop most closely resembles that of CD58.  For ex- 
ample, the conformation  of the CC' loop was modeled on the 
corresponding loop in rat CD2 (involving a two-residue deletion 
in human CD2).  The C'C" loop was formed by deleting E52 in 
human CD2, which is a bulge at the beginning of the C" strand, 
and preserving the conformation of the turn. The C"D loop was 
modeled on that of CD4 in order to form a salt bridge between 
residues R52 and D71. This salt bridge is conserved in most Ig 
domains, but is not present in CD2. For the FG loop, the align- 
ment of the F and G strands means that if the strands form a 
r  this puts proline 80 in the first position of a four-residue 
~-turn; this is unusual and introduces a conformational distortion. 
There is no similar loop in the above structures but one was found 
in the FG loop of a mouse Ig H chain constant domain (Brook- 
haven structure  1FAI) and this was incorporated into the model. 
The side chain conformations were chosen using the above struc- 
tures as a guide and ensuring  that no severe steric clashes were 
created. 
In the second model, a secondary structural alignment based 
on human CD2 was used and the conformation of loops chosen 
to provide best conformity with the experimentally derived mAb 
and CD2 binding results. Both models were energy minimized  using 
the Amber force field in the Discover program from Biosyn Tech- 
nologies (San Diego, CA). The two CD58 models differ slightly 
in the alignment of the A and C" strands, and in the EF loop (data 
not shown). However, they are in agreement as to the alignment 
of the important F, G, C, and C' strands where most of the muta- 
tions are located. 
Results and Discussion 
Sequence Alignment of the Adhesion Domains of CD58, CD48, 
and CD2.  The NMR studies of rat and human CD2 adhe- 
sion domains show that each adopts an Ig fold (31-33). These 
solution structures were confirmed and extended by x-ray 
crystallography analyses of the entire rat CD2 ectodomain 
(34). The second domain was found to be Ig-like as well and 
connected to the membrane-distal first domain by a flexible 
hinge region. Given the weak but nevertheless significant ho- 
mology between the extracellular segments of human CD2 
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Figure  1.  Alignment of amino acid sequences 
in  the adhesion  domains  of CD58, CD48,  and 
CD2. The amino acid sequences were aligned as 
described in Materials and Methods. The positions 
for the/~ strand and loop residues in the human 
CD2 adhesion domain (32, 33) are shown as defined 
by NMR analysis. Residues that are conserved be- 
tween all sequences are boxed and shaded. CD58 
residues  that  are  involved in binding  CD2  are 
shown  in either  closed circles (strong  effects) or 
half-closed circle (partial effect). Analyzed residues 
not involved in binding CD2 are shown in open 
circles (no effect). Sheep CD58 sequence data are 
available from GSDB/DDBJ/EMBL/NCBI DNA 
under accession number D28584. 
and human CD58, it is likely that CD58 also consists of two 
Ig-like domains  (28). 
The NH2-terminal  domain (amino acid  [aa]  1 1-93)  of 
CD58 has been shown to contain the CD2 binding region 
(17). Fig.  1 offers an alignment between human CD2 and 
human CD58 adhesion domains and indicates the position 
of the CD2/3 strands as defined by NMR. The conservation 
of multiple key amino acid residues found in Ig domains im- 
plies that the CD58 adhesion domain adopts an Ig-fold. An 
invariant tryptophan (W28) in the predicted C strand is present 
at  the  same position  in  all  known  Ig  supergene  family 
members. In addition,  other CD58 residues including V13, 
F15, V35, R52, L62, I64, D71, Y75, L90, and V92 are con- 
served among Ig family members (Fig. I and data not shown). 
R52 at the end of the predicted C"D loop and D71 in the 
predicted EF turn presumably form a salt bridge that is char- 
acteristic of most Ig molecules. This salt bridge is absent in 
CD2. In addition,  the human CD58 adhesion domain, like 
the CD2 adhesion domain, also differs from conventional Ig 
domains in lacking two cysteine residues which form an in- 
tradomain disulfide bond in almost all Ig domains (28-30). 
Valine (V17) at the end of the predicted CD58 B strand and 
methionine (M77) at the predicted F strand presumably func- 
tion in lieu of the cysteine residues to mediate hydrophobic 
contacts (Fig. 1). In this regard, replacement of the corre- 
sponding hydrophobic residues on rat CD2 in the B and F 
strands by cysteines  through site-directed mutagenesis showed 
that a disulfide bond forms at this position (49). Hydrophobic 
residue (V13) is located near the start of the B strand and 
Y75 is located two residues NH2-terminal to M77, near the 
beginning of the F strand.  These hydrophobic residues are 
hallmarks of Ig domains and form part of the hydrophobic 
core of the Ig domain (30). Fig. 1 also depicts the sequence 
similarity between the NH2-terminal domain of sheep CD58 
and human CD2 as well as human CD48 and human CD2. 
Human CD48 consists of two Ig-like domains as well (35). 
As noted, there is considerable homology among the NH2- 
terminal domains of the three human CD2 ligands (human 
CD58, human CD48, and sheep  CD58): 55% between human 
CD58 and sheep CD58 and 30% between human CD58 and 
human CD48 (Fig. 1). These ligands all possess key conserved 
Ig domain residues. 
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Generation and Expression of Human CD58 Mutant Mole- 
cules.  Residues conserved among at least several  of the CD2 
ligands seem the most obvious candidates to be implicated 
in the CD2 contact site. With these criteria in mind, we 
selected 15 conserved residues in domain I which are charged 
and surface exposed (Fig. 1) for alanine scanning-based site- 
directed mutagenesis studies. In addition,  three charged but 
nonconserved residues each localized in the predicted C'C" 
loop, C" and G strands were also mutagenized. As shown 
in the schematic representation of the human CD58 domain 
(Fig. 2), 10 of the 18 residues mutated map within/3 strands: 
￿9  TS2/9 
￿9  IA3 
￿9  IH10 
￿9  IA2 
93 
Figure 2.  Location  of CD58  point mutations  and  anti-CD58 mAb 
binding sites on a molecular model of the adhesion domain of human CD58. 
Ribbon diagram  representation  of a "MOLSCRIPT" drawing (56, 57) 
showing the predicted  AGFCC'C" B sheet in the front (light) and the 
BED sheet in the back (dark) with residue numbers indicating the begin- 
ning and end of each/3 strand.  Residues analyzed by site-directed muta- 
genesis to identify binding sites for CD2 and various anti-CD58 mAbs 
are shown circled and their positions on the CD58 model, except for P80, 
are based on both sequence alignment and CD2/3 strand assignments (Fig. 
1, and 32, 33). Point mutants that affect anti-CD58 mAb binding are in- 
dicated with symbols:  TS2/9 (O), 1A3 (11), 1H10 (A), and  1A2 (V). Figure  3.  Binding  of  Jurkat cells to wt or mutant CD58-expressing CHO cells. CHO cells expressing wtCD58 (A) or K34A mutant CD58 (B) 
molecules  were analyzed  for their ability  to interact with  Jurkat cells and viewed  under an inverted  phase-contrast  microscope  (Leitz)  at a magnification 
of 1080. (Insets) Fluorescence  histograms of 5,000 cells of the indicated  CHO transfectants  with anti-CD58 (RB202) (dark curve) followed  by FITC- 
conjugated goat anti-rabbit Ig or the second antibody  alone (light curve). (X-axis) Mean channel  fluorescence  over a 4-log scale; (y-axis) cell number. 
two residues  in the G strand (D84 and K87), two residues 
in the F strand (E76 and E78),  three residues in the C strand 
(E25,  K29,  and K30),  one residue in the C' strand (E37), 
one residue in the C" strand (R44), and one residue in the 
D strand (D56). The other eight residues tested map within 
the predicted loops:  three residues  in the CC' loop (K32, 
D33,  and K34), one residue in the C'C" loop (E39),  two 
residues in the C"D loop (K50 and R52), and two residues 
in the EF loop (E72 and D73).  The wtCD58 molecule or 
individual mutants were transfected into CHO cells and stable 
lines expressing these molecules were screened by indirect im- 
munofluorescence using a rabbit anti-CD58 heteroantiserum 
(Rb202).  CHO lines expressing CD58  molecules at levels 
comparable or higher than wtCD58  were selected by im- 
munofluorescence and cell sorting. In this way, we could exo 
dude that loss of CD2 binding activity was related to a low 
CD58  copy number on the CHO cells. 
Specific  Cell-based Adhesion Assay to Analyze  the Interaction 
of  Human CD2 with CD58 Mutants.  The interaction between 
human CD2 and CD58 was studied in a cell-cell adhesion 
assay using CD2 + Jurkat cells and CHO cells  transfected 
with CD58 cDNA encoding either wtCD58 or one of the 
mutant molecules. Previous studies using this assay showed 
that the binding of Jurkat  cells  to CD58 + CHO cells is 
strictly dependent on the CD2-CD58 interaction (24). The 
photomicrographs in Fig.  3 compare the results of a repre- 
sentative binding experiment between Jurkat and the wtCD58 
CHO transfectant on the one hand (Fig. 3 A) and between 
Jurkat and a CD58 point mutant (K34A) which completely 
disrupts binding on the other hand (Fig. 3 B). Note the readily 
apparent aggregates between the round, relatively small Jurkat 
cells  and  the large,  fusiform CHO  cells  transfected with 
wtCD58. In contrast, virtually no aggregates are formed be- 
tween Jurkat cells and the K34A CD58 transfectant. This 
result is noteworthy particularly because the level of CD58 
surface expression  on K34A CHO transfected cells is more 
than threefold that on the wtCD58 CHO transfectant (Fig. 
3  insets,  and Table 1). 
CD58 Point Mutants.  The results of experiments with all 
CD58 mutants expressed in CHO cells are summarized in 
Table 1. The percentage of  binding for individual CD58 mu- 
tants was calculated  relative  to wtCD58 using a previously 
described  semi-quantitative CHO binding assay with 51Cr- 
labeled Jurkat cells (24). To exclude the possibility that a loss 
of CD2 binding capacity was simply a consequence of global 
disruption of the three-dimensional structure of the CD58 
adhesion domain, each mutant was analyzed with a panel 
of eight anti-CD58 mAbs directed at four distinct native epi- 
topes of the CD58 adhesion domain (termed epitopes 1-4) 
as defined by prior cross blocking studies (49).  The struc- 
tural integrity of the CD58 adhesion domain point mutants 
was assessed by reactivity with three mAbs specific for epi- 
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CD58  Localization Level  of CD58  anti-CD58 mAb Binding 
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Levels of CD58 expression for the 
point mutants were compared with 
wtCD58 and are expressed as a ratio 
of specific  linear  mean channel  fluores- 
cence intensity  of Rb202 heteroantise- 
rum binding to the mutant versus the 
wt. Percent  binding was calculated  by 
taking a ratio of total  Jurkat cell  bind- 
ing (average  cpm) to each mutant rela- 
tive to the wtCD58 expressing  CHO 
cells. The standard  deviations  are shown 
as a percentage of the total binding. 
The effect  of anti-CD58 mAbs on point 
mutants were compared  with wtCD58 
by taking a ratio of the relative  mean 
fluorescence (FL) intensities of mAb 
binding and Rb202 binding. The reac- 
tivities of anti-CD58 mAb binding was 
calculated as follows: [(FL of mAh 
binding to mutant -  FL of control 
mAb binding to mutant)/(FL  of Rb202 
binding to mutant -  control  sera  bind- 
ing to mutant)]/[(FL  of mAb binding 
to wt  -  FL of control mAb binding 
to wt)/(FL of Rb202 binding to wt 
-  FL of control sera  binding to wt)]. 
Reactivities <0.4 are denoted as sig- 
nificant effects (m), and >0.4 as no 
significant effects  (E]). Results are rep- 
resentative of a minimum of two ex- 
periments for Jurkat cell binding and 
for mutants that affect  mAb binding. 
tope 1 (TS2/9, 1A3,  and 1H10);  one mAb specific for epi- 
tope 2 (1A2); three mAbs specific for epitope 3 (1C4,  IC5, 
and 1F4);  and one mAb specific for epitope 4 (PAK). Our 
results show that epitope 1 and 2 mAbs map to C', C", and 
G/3 strands and CC', C'C" and C"D loop regions (Fig.  2, 
and Table 1). Consistent with the functional evidence that 
epitope 1 mAbs block E rosette formation, three of the six 
residues (K87, E37, and K34) to which mAbs TS2/9, 1A3, 
and 1H10 map are involved in CD2 binding (Table  1). By 
way of contrast, epitopes 3 and 4 mAbs failed to block the 
CD58-CD2 interaction and mapped to none of the residues 
tested on the AGFCC'C" surface.  It is thus likely that epi- 
tope 3- and 4-specific mAbs map to the BED face of the CD58 
adhesion domain or alternatively, to another surface distinct 
from the CD2 binding region. The epitope 2 mAb cross blocks 
the binding of both epitopes I and 3 (49) and therefore may 
map to a region that straddles the major j8 strand surfaces. 
Our data are consistent with the mapping of 1A2 to the C"D 
loop (K50). Presumably, the ability of 1A2 to block CD2 
binding may be mediated by steric inhibition as the excluded 
volume of the antibody footprint is large relative to the CD58 
adhesion domain.  The mutagenesis data herein provide an 
additional level of refinement to mAb mapping studies as they 
indicate that even within the epitope I group of mAbs, none 
react with CD58 in precisely the same way (Table  1). The 
differential effect of CD58 point mutants on mAb binding 
is evidence that mutations do not cause an overall disruption 
in the three-dimensional structure of the adhesion domain 
of CD58.  Therefore, we interpret the effects of the CD58 
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mutants on CD2 binding to be a direct consequence of the 
mutated residue on CD58. 
CD2 Binding Site on CD58.  The cellular binding analysis 
of 18 individual CD58 adhesion domain point mutants ex- 
pressed in CHO cells  identified eight charged residues  on 
the  predicted  AGFCC'C"  surface  of  the  NH2-terminal 
CD58 adhesion domain whose mutation to alanine disrupts 
the binding of CD2 + Jurkat cells. The K34A CHO trans- 
fectant binds to Jurkat cells at only 1% the level of the wtCD58 
CHO transfectant. In addition, the D33A, E37A, and K87A 
CD58 mutants show <30% binding to the CD2 + T  cells. 
Four other CD58 point mutants (E25A, K29A, K30A, and 
K32A) exhibit less dramatic but nonetheless clear-cut effects 
on CD2 binding (35-68% wt levels). These eight residues 
on the adhesion domain of CD58 therefore represent poten- 
tial contact sites for CD2 binding. As shown in Fig. 4, A  and 
B, it is predicted that their side chains contribute to a charged 
patch covering a surface area of ~600 A 2 on the AGFCC'C" 
surface  of CD58.  It is noteworthy that this surface area is 
somewhat less  than the 770~, z on the AGFCC'C" face of 
the CD2 adhesion domain known to be involved in the binding 
of  human  CD58  (43).  The  area  is  also  less  than  the 
650-690A 2 surface contact mediating the homophilic inter- 
action involving the AGFCC'C"  surfaces  of two rat CD2 
molecules in the rat CD2 crystal structure (34). Given that 
we only probed surface-exposed charged residues on CD58, 
it is likely that some hydrophobic and/or polar residues may 
participate in the CD2 binding surface of CD58, thereby con- 
tributing to a larger area of  contact. For example L27, which 1866  CD2-CD58 Molecular Interaction 1867  Arulanandam et al. Figure  4.  Delineation  of the CD2 binding site on CD58 and possible 
CD2/CD58 docking orientations. The CD2 binding site on CD58 is a 
highly charged surface area on the predicted  AGFCC'C" surface of the 
adhesion domain  of CD58. Shown  is a stereo or-carbon trace model (A) 
and a corresponding  space-  filling  model  (B). Possible  docking  orientations 
for the CD2 (white) and CD58 (blue) interactions  based on the rat CD2 
dimer (C) or CD8 ot homodimer  (/9). A space-filling  model  for the docking 
orientation  is shown  (E). Residues  on CD58 that showed  <30% (red) (D33, 
K34, F.37, and K87) or 30-75% (yellow) (E25, K29, K30, and K32) of 
wt binding to CD2 when substituted  with alanine are indicated. Previ- 
ously  defined  CD2 residues  affecting  CD58 binding  (43) are also  depicted. 
The COOH-terminal segment of the G strand of the CD58 and CD2 
adhesion domain is indicated by an open box. 
is predicted to be surface exposed and lies between E25, K29, 
K34, and E37, may be such a hydrophobic residue (Fig. 4 B). 
Our results are generally consistent with those of Miller 
et al. (17) who performed deletional mutagenesis to identify 
CD58 sequences involved in binding human CD2. Deletion 
of sequences between residues 11 and 70 on CD58 led to both 
a loss of CD2 and anti-CD58 mAb binding, whereas dele- 
tion of residues  131-180 in the second domain did not affect 
either CD2 or anti-CD58 mAb binding. However, in con- 
trast to our finding that K87A almost completely abrogated 
CD2 binding, they reported that a deletion of CD58 residues 
71-130  does not affect CD2 binding. Since their result is a 
negative one, the finding is difficult to interpret especially 
since another residue in the mutant structure might func- 
tion in lieu of K87. 
Of the four CD58 residues  (D33,  K34, E37,  and K87) 
that apparently play the greatest role in CD2 binding (<30% 
wt binding),  K34  is  conserved among human and  sheep 
CD58, and human CD48 and human CD2 (Fig. 1, and Table 
1). Similarly, E37 is conserved in human CD48 and the com- 
parable residue in sheep CD58 and human CD2 is the related 
amino acid glutamine. K87 is also conserved between human 
CD58 and CD48. In view of the conservation of K34, E37, 
and K87 in human CD58 and CD48 and their observed func- 
tional effects on the CD2-CD58 interaction, it is likely that 
the corresponding residue in CD48 is involved in the CD2 
interaction. If this is so, CD48 and CD58 may bind to CD2 
in a similar way. In contrast, the other five charged CD58 
residues (E25,  K29, K30, K32, and D33) which contribute 
to CD2 binding, are conserved  between human and sheep 
variants of CD58 but not human CD48. These residues may, 
at least in part, be responsible  for the higher affinity of the 
CD58 interaction with human CD2 (Kd ~10-6 M) relative 
to  the  human  CD48  interaction  with  human  CD2  (Kd 
r~10 -4 M).  Polar  and/or  hydrophobic residues  yet  to be 
identified may also contribute to the higher-affinity interac- 
tion between CD2 and CD58. Collectively, these data also 
suggest that human and sheep CD58 interact with CD2 in 
a similar manner, consistent with our prior analysis of mu- 
tant CD2 molecules (43). In that study, it was observed that 
CD2 mutations which disrupted the sheep CD58 interac- 
tion also disrupted the human CD58  interaction. 
Possible Docking Orientation of CD58 and CD2.  The muta- 
tional data for CD58 presented herein and for CD2 presented 
elsewhere  (43) define the area of interaction between these 
proteins. To develop a model of the CD2-CD58 complex, 
we considered as paradigms several examples of crystaUographi- 
cally defined docking orientations between Ig-related mole- 
cules. These include the known interaction between Ig VH 
and VL domains, between human CD8  c~ subunits in the 
CD8 or-or homodimer and between two CD2 molecules in 
the rat CD2 crystal structure (34, 46, 47). Since the packing 
between CD8 ot subunits is close to that between V. and 
V~,  the latter  were  not  studied separately.  However,  the 
orientation of molecules in the rat CD2 dimer structure is 
distinct from that of CD8 or Ig dimers (34).  In the CD8 
~-t~ homodimer structure, the molecular association between 
subunits involves main chain hydrogen bonding between the 
C' strand of one molecule and the G  strand of the other. 
In the rat CD2 dimer, the CC' and FG loops are shortened 
compared to CD8, and the relative orientations of their do- 
mains differ by ~60 ~ from that of CDS. This reduces the 
extent of the hydrogen bonding interaction to the beginning 
of the C' and G  strands where they join the CC' and FG 
loops,  respectively. 
Based on these examples,  two possible docking orienta- 
tions for the CD58-CD2 interaction were created. The first 
docking orientation (Fig. 4 C) was constructed using a model 
of the rat CD2 dimer: one rat CD2 adhesion domain was 
replaced by the human CD2 NMR structure by least squares 
superimposition of the C~ atoms of residues in the binding 
sheet and the other domain substituted by the human CD58 
model. As shown in Fig. 4 C,  this orientation brings the 
FG and CC' loop of CD2 and CD58 adjacent to each other. 
In this docking orientation, the COOH-terminal end of the 
G  strands of CD2 and CD58 point away from each other 
in essentially  opposite directions, presumably towards two 
separate cell membranes. Fig.  4 D  represents  a second pos- 
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c~ homodimer which bring the FG loops of CD2 and CD58 
near one another as shown. If this orientation is correct, then 
the COOH-terminal  segments of the G strand in CD2 and 
CD58 are only separated by an angle of ~60 ~  Given that 
the crystal structure of the two domain rat CD2 molecule 
identifies an angle of ~160 ~ between the adhesion domain 
of CD2 and the second domain plus COOH-terminal  stalk 
region (34), it is plausible that the adhesion domains of CD2 
and CD58 could approach one another  from two separate 
cell membranes  in  such a manner. 
Both docking models take into account all the side chains 
implicated  in  binding  with  one  exception.  In  the  CD2 
dimer-based model (Fig. 4 C), K87 on CD58, which is in- 
volved in CD2 binding, is an outlier and makes no contacts 
with CD2.  In contrast,  in the CDSot-based model (Fig.  4 
D), it is on the edge of the binding interface and can be in- 
volved in direct interaction. This difference tends to support 
the  CD8ot-based model as more representative  of the real 
CD2-CD58 docking orientation.  On the other hand,  our 
efforts at de novo docking of CD2  and CD58  suggest an 
orientation close to the CD2 dimer-based model that readily 
provides K87 with contacts to CD2 (data not shown). Hence, 
we cannot make a definitive statement about the docking orien- 
tations of CD2 and CD58 at present. A space-filling model 
of the CD2-CD58 interaction in the CD8-based orientation 
(Fig. 4 E) shows that the nature of the contact surface size 
and  shape is also reasonable. 
Implications for the CD2-CD58 Interaction.  Our prior muta- 
genesis analysis  shows that the CD58 binding site on CD2 
covers --770A  2 on the AGFCC'C" face of the CD2 ~ barrel 
(43).  This  site contains  3  strand  residues in  the  COOH- 
terminal half of the F strand (including K82 and Y86), the 
top of the C strand (D32 and K34), and the C' strand (Q46), 
which are all solvent exposed. In addition,  several exposed 
residues on the FG loop (G90, K91, N92, and V93), the CC' 
loop (K41 and K43) and the C'C" loop (R48 and K51) form 
this site. The current mutagenesis on CD58 has uncovered 
the other surface of the interaction involving five positively 
charged residues (K29, K30, K32, K34, and K87) and three 
negatively charged residues (E25, D33,  and E37).  In light 
of the seven positively charged and one negatively charged 
CD2 residues involved in this site, it appears there is an excess 
of positive charge.  This excess positive charge may be satisfied 
by interaction with water. Alternatively, the positive charge 
may also be satisfied  by negatively charged side chains that 
appear not to be crucial for binding (E39, E76, and E78) or 
are near the site (E42 and E74) but whose contribution  to 
CD2 binding is yet to be determined. The ability of sulfated 
dextrans to inhibit the CD2-CD58  interaction  is probably 
a consequence of direct binding of these polymers to the posi- 
tively charged CD2  and/or  CD58  surface (50). 
The mapping  of the CD2 binding  site  to the predicted 
AGFCC'C" surface of the CD58 adhesion domain shows that 
the major/3 sheet surfaces mediating interaction between CD2 
and CD58 are the same as those mediating dimerization of 
other Ig-variable domains including Ig, CD8c~, and rat CD2 
(34, 46, 47). In the CD8ot homodimer and V,-VL interac- 
tions, the G  and C' strands contain conserved/3 bulges lo- 
cated at the dimer interface which are believed to facilitate 
dimerization  (47,  51,  52).  The  CD58  residue E37 on the 
predicted C' strand and residues K32, D33, and K34 adja- 
cent to the start of this strand and K87 within the predicted 
G strand are all important for CD2 binding.  These residues 
may actually be components of equivalent 3 bulges. Support 
for this notion is the finding that the corresponding residue 
in the CD2  C'  strand  (Q46)  and residues adjacent  to this 
(K41 and K43) are critical for CD58 binding (43, 53). They 
are located on the corresponding/3 bulge of CD2 (32, 33). 
Mutations of G90, K91, N92, and V93 near the start of the 
CD2 G  strand disrupt  CD58 binding but there is no evi- 
dence for a 3  bulge in the G strand (33).  The prevalence of 
charged residues in the predicted CD2-CD58 interface noted 
above appears to differ from the predominant  hydrophobic 
interaction  among residues found at  the  site  of VH-VL do- 
main packing  (51).  However, if there is a 3  bulge located 
in the G strand of CD58 involving residues K87, F88, and 
F89, then this bulge would expose hydrophobic side chains 
that would involve hydrophobic contacts between CD2 and 
CD58. 
The  present  analysis  of the  molecular  interface  in  the 
CD2-CD58  complex offers a first consideration of the na- 
ture of a receptor-ligand  pair involving two Ig supergene family 
members. Such interactions are distinct from those between 
V domains in idiotype-anti-idiotype complexes where major 
surface contacts are mediated via the CDR1  (BC),  CDR2 
(C'C"), and CDR3 (FG) loops (54, 55). They are also different 
from the interaction  between Ig constant  region  domains 
which involve the BED/3 sheet surface (57). Given that ei- 
ther of the two CD2-CD58 docking orientations might facili- 
tate conjugate formation between T lymphocytes and APCs, 
the precise orientation of the interaction awaits elucidation 
by structural analysis of a CD2-CD58 complex. Alternatively, 
it may be possible to infer the correct docking mode by fur- 
ther mutagenesis involving reciprocal charge reversals in CD2 
and CD58. 
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